摘要
目的:研究PD-L1在结直肠癌(colorectal cancer,CRC)中的表达及临床意义。方法:选取2015年1月至2016年1月在郑州大学附属肿瘤医院接受CRC根治性手术的患者210例,分为微卫星高度不稳定(high-frequency microsatellite instability,MSI-H)、微卫星低度不稳定(low-frequency microsatellite instability,MSI-L)、微卫星稳定(microsatellite stable,MSS)3个组,采用免疫组织化学法检测各组织标本中细胞程序性死亡配体1(Programmed cell death 1 ligand 1,PD-L1)的表达,分析PD-L1在各型CRC中的表达特点。结果:PD-L1在低分化CRC中的表达高于中、高分化CRC(P<0.05),PD-L1在MSI-H的CRC中阳性率为75.8%,在MSIL/MSS中的阳性率为9.3%,两组比较差异具有统计学意义(P<0.05)。结论:PD-L1在部分CRC癌组织中阳性表达,尤其是在MSIH的CRC阳性率显著高于MSI-L及MSS的CRC。PD-L1阻断剂对MSI-H的CRC患者疗效可能更好。
Objective：To investigate the expression and clinical significance of PD-L1 in colorectal cancer （CRC）. Methods：A total of 210 CRC patients who accepted radical surgery in our hospital from January 2015 to January 2016 were divided into three groups, namely, high-frequency microsatellite instability （MSI-H）, low-frequency microsatellite instability （MSI-L）, and microsatellite stable （MSS）. The expression of PD-L1 was detected by immunohistochemistry, and the expression characteristics of PD-L1 in different types of CRC were analyzed. Results：CRC cases with low differentiation had a higher expression of PD-L1 than CRC patients with high differ-entiation （P〈0.05）. PD-L1 had a positive rate of 75.8%in the MSI-H group and a rate of 9.3%in the MSI-L and MSS groups, wherein the difference between the two groups was statistically significant （P〈0.05）. Conclusion：PD-L1 was positively expressed in some CRC tu-mor tissues, and its positive rate was significantly higher in MSI-H than in MSI-L and MSS. The therapeutic effect of a PD-L1 blocker for patients with MSI-H CRC might be preferable.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2017年第12期589-593,共5页
Chinese Journal of Clinical Oncology
作者简介
冯稳：专业方向为消化道和胸部肿瘤的病理研究与诊断。E-mail：manfengwen@126．com
通信作者：夏庆欣13838173710@139．com
